This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Fresenius Medical Care Groupe France SAS
Fresenius Medical Care Groupe France SAS, a prominent subsidiary of Fresenius Medical Care AG & Co. KGaA, is headquartered in France and operates extensively across Europe. Founded in 1996, the company has established itself as a leader in the healthcare industry, specialising in products and services for individuals with chronic kidney failure. Fresenius Medical Care is renowned for its innovative dialysis products, including state-of-the-art dialysis machines and comprehensive renal care services. The company’s commitment to quality and patient-centric solutions has positioned it as a trusted provider in the market. With a strong focus on research and development, Fresenius Medical Care continues to achieve significant milestones, enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Fresenius Medical Care Groupe France SAS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius Medical Care Groupe France SAS's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius Medical Care Groupe France SAS, headquartered in France, currently does not report specific carbon emissions data for the most recent year. The organisation is a current subsidiary of Fresenius Medical Care AG, which provides emissions data and climate commitments at a higher corporate level. As part of its climate strategy, Fresenius Medical Care AG has set various reduction initiatives, although specific targets for Fresenius Medical Care Groupe France SAS are not detailed. The company is involved in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are cascaded down from the parent organisation. However, no specific reduction targets or achievements have been disclosed for the French subsidiary. In summary, while Fresenius Medical Care Groupe France SAS is part of a larger corporate family committed to climate action, specific emissions data and reduction targets for this entity are currently unavailable. The company is aligned with broader industry efforts to address climate change through its parent organisation's initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Medical Care Groupe France SAS is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
